1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Price Chart
4. Valuation
5. Offer Terms
6. Financial Statements
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
MIRA
Listed on
2023-08-03
Sector
Health Care
Subsector
Pharmaceuticals
Offer Price
$7.00
first filed $6.00–$8.00Shares Offered
1.27M
14.78M
$103.2M
8.6%
Implied Upside vs Midpoint
Description
We are an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Our target patient population is also typically presenting with chronic pain. Our drug candidate, MIRA1a, if approved by the FDA, may be a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by us, we believe that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain by potentially striking a balance between the beneficial effects of THC and CBD. MIRA1a achieves this by selectively targeting the cannabinoid type 1 (“CB1”) and cannabinoid type 2 (“CB2”) receptors. Cannabinoid receptors, located throughout the body, are part of the endocannabinoid system, which is involved in a variety of physiological processes and responses including appetite, pain-sensation, mood, and memory. With respect to THC, our pre-clinical studies have shown that MIRA1a may have less potency at CB1 but maintains high activation at CB2. Since CB1 activation corresponds to intoxication, we believe that MIRA1a is potentially less intoxicating than THC while still providing beneficial therapeutic effects. In addition, by curbing the negative effects of THC (e.g. cognitive impairment), preclinical studies suggest that MIRA1a may be capable of unmasking positive therapeutic effects not previously seen with THC (e.g. cognitive performance enhancement). --- Our corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland 21205. Our telephone number is 737-289-0835. Our principal website address is www.mirapharmaceuticals.com.
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
Net cash / market cap | 0.3% | 1.3% | ||
Debt / equity | 0.00 | 0.00 | ||
Current ratio | 0.36 | 0.84 | ||
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||
= Priced at $7.00, 0% above the midpoint of the first filed range ($6.00–$8.00, 2023-07-14).
Each filing is plotted ahead of the first trading day on the price chart.
| Filed | Form | Price range | Price | Shares offered | Deal size |
|---|---|---|---|---|---|
| 2023-07-14 | S-1/A | $6.00–$8.00 | — | 1,000,000 | $7.0M |
| 2023-07-21 | S-1/A | — | $7.00 | 1,200,000 | $8.4M |
| 2023-07-28 | S-1/A | — | $7.00 | 1,275,000 | $8.9M |
| 2023-08-04 | 424B4 | — | — | 1,560,000 | — |
| 2023-08-04 | 424B1 | — | $7.00 | 1,275,000 | $8.9M |
MIRA Pharmaceuticals, Inc. income statement and balance sheet, FY Dec 2022 to FY Dec 2025, as reported in SEC filings.
| Metric | FY Dec 2022 | FY Dec 2023after listing | FY Dec 2024after listing | FY Dec 2025after listing |
|---|---|---|---|---|
| Net income | ($7.1M) | ($12.0M) | ($7.9M) | ($10.4M) |
| Metric | FY Dec 2022 | FY Dec 2023after listing | FY Dec 2024after listing | FY Dec 2025after listing |
|---|---|---|---|---|
| Total assets | $858K | $4.9M | $2.9M | $11.1M |
| Total liabilities | $1.5M | $558K | $723K | $702K |
| Total equity | ($596K) | $4.4M | $2.2M | $10.4M |
| Cash & equivalents | $351K | $4.6M | $2.8M | $6.3M |